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Introduction:Above knee (AK) femoropopliteal bypass remains a sufficient and durable therapy for long occlusions of the
superficial femoral artery in the era of endovascular repair. A novel, precuffed expanded polytetrafluoroethylene (ePTFE)
graft that was designed for AK femoropopliteal bypass (Dynaflo, Bard Peripheral Vascular Inc, Tempe, Ariz) has been
available for clinical use since March 2005, promising better patency rates by optimizing the hemodynamic patterns
within the distal anastomosis.
Methods: A prospective, multicenter, nonrandomized study was performed to investigate the clinical results of the Dynaflo
graft. Primary end points were patency rates, limb salvage, and complications.
Results:Between March 2005 and August 2007, the Dynaflo graft was used in 135 AK bypasses in 134 patients (110 men)
with a mean age of 66 years. Indication for revascularization was claudication in 99 (73%) and critical ischemia in 36
(27%). With a mean follow-up of 18 months the 6-, 12- and 24-month primary patency rates were 90%, 83% and 72.5%
and the secondary patency rates were 93%, 88.6% and 82.2%, respectively. The cumulative limb salvage rate at 24 months
was 95%. Complications were observed in 39 patients (29%), with bypass failure (29 cases) and significant thrombus
accumulation at the distal anastomosis (4 cases) being the most severe.
Conclusion: This study presents the first clinical results of a novel ePTFE graft for supragenicular revascularization. The
implantation of the Dynaflo graft seems to be safe and feasible for AK bypass, achieving acceptable medium-term patency
rates. Nevertheless, long-term results have to be awaited, and prospective comparative studies are warranted. (J Vasc
Surg 2009;49:1203-9.)Infrainguinal femoropopliteal above knee (AK) bypass
for the treatment of peripheral arterial disease (PAD) with
long occlusion, defined as TransAtlantic Inter-Society
Consensus (TASC) II C lesions of the superficial femoral
artery (SFA), has better long-term results than percutane-
ous transluminal angioplasty (PTA).1 Autologous great
saphenous vein is the optimal graft material for below knee
(BK) as well as AK femoropopliteal reconstructions.2-4
Absence of suitable vein or choice of the surgeon to pre-
serve the vein for future revascularizations prompts the use
of prosthetic grafts.
Efforts to improve the patency rates of the established
femoropopliteal bypasses with expanded polytetrafluoro-
ethylene (ePTFE) or Dacron grafts have been made by
modifying the inner surface of ePTFE or Dacron (heparin-
bonded grafts), or by use of human umbilical vein
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doi:10.1016/j.jvs.2008.11.097(HUV).4-6 The interposition of vein at the distal anasto-
mosis of prosthetic bypasses is reported to improve patency
rates of infragenicular bypasses by optimizing the hemody-
namic patterns.7,8
Precuffed BK femoropopliteal grafts seem to achieve
similar patency rates compared with vein-cuff interposition
at the distal anastomosis.9,10 The same principle of pre-
cuffed distal anastomosis was introduced for AK femoro-
popliteal bypasses with the Dynaflo graft (Bard Peripheral
Vascular Inc, Tempe, Ariz; Fig 1). This study reports the
first early clinical results of a prospective multicenter cohort
study with this novel graft.
MATERIALS AND METHODS
Study design. A prospective, multicenter, nonran-
domized study was performed to investigate the clinical
results of the new Dynaflo prosthetic graft for AK bypass
(Fig 1). The study included all consecutive adult patients
with claudication (Rutherford 2 to 3) or chronic critical
limb ischemia (Rutherford 4 to 6) who were considered
suitable for elective revascularization by use of a supra-
genicular prosthetic bypass graft, provided the patients had
given written consent to take part in the study and in
follow-up. Primary end points were patency rates, limb
salvage, and complications.
Patients with claudication were only included after
completion of exercise training without sufficient improve-
ment (50%) and when no percutaneous treatment (an-
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or reasonable with respect to long-term results.
All patients were presented in an interdisciplinary con-
ference with vascular surgeons, angiologists, and interven-
tional radiologists because certified vascular centers in Ger-
many are obligated to discuss less invasive therapeutic
options. To achieve homogeneity in the group of patients
undergoing AK femoropopliteal bypass between the three
centers, no patients with an occlusion length of the super-
ficial femoral artery of 15 cm were included before un-
dergoing an endovascular approach.
A relevant (50%) stenosis of the deep femoral artery
that could be treated with patch angioplasty or another
reconstruction was an exclusion criterion. A nonseverely
calcified segment of adequate length of the proximal pop-
liteal artery, as estimated by the surgeon, had to be available
to ensure an exact configuration of the cuff without mod-
ification. Adequate inflow to the common femoral artery
was a prerequisite for inclusion in the study. If not present
or if at least improvable, adequate inflow had to be estab-
lished before or during the operation. Adequate inflow was
considered present when triphasic flow in the common
femoral artery was found using color-coded Doppler ultra-
sound imaging or when the iliac vessels were angiographi-
cally free of 30% stenosis or multiple stenoses. The Dy-
naflo grafts were implanted by the 11 vascular surgeons of
the participating centers as well as by five vascular trainees
under supervision.
Other exclusion criteria were emergency operation,
pregnancy, malignant disease, short (1 year) life expect-
ancy, popliteal aneurysmal disease, and extended infection
of the affected limb, which might put the implanted graft at
risk of infection.
Preoperative assessment. The PAD-specific preoper-
ative workup of the patients included evaluation of ankle-
brachial index (ABI), free-of-pain walking distance on the
treadmill with 3 km/h speed and 12% inclination for pa-
Fig 1. Dynaflo (Bard Peripheral Vascular Inc, Tempe, Ariz) ex-
panded polytetrafluoroethylene graft with the precuffed distal end
designed to optimize hemodynamics within the distal end-to-side
anastomosis.tients with claudication, and conventional digital subtrac-tion angiography (DSA). DSA was the preferred pre-
operative imaging modality in patients who were
planned to undergo surgical treatment, but computer
tomography angiography (CTA; n  1) or magnetic reso-
nance angiography (MRA; n  5) were also accepted in
selected cases. The inflow to the common femoral artery
was assessed either with color-coded Doppler ultrasound
imaging (triphasic flow) when only a fine-needle angiogra-
phy had been performed as preoperative diagnostic modal-
ity of the affected limb or angiographically when angiogra-
phy of the aortoiliac vessels was available.
Operation. The popliteal artery was exposed in its first
segment by a supragenicular medial approach. Inspection
and palpation confirmed its suitability as a recipient artery
for an AK bypass. Exposure of the common femoral as well
as the proximal deep femoral artery and the proximal SFA
was performed by an infrainguinal incision. The Dynaflo
graft was implanted extra-anatomically or anatomically
with the help of a tunneling instrument, preventing kinking
of the graft proximal to the distal cuff. Systemic heparin was
administered at a dose of 5000 IU, and the popliteal artery
was clamped.
After longitudinal arteriotomy, the distal anastomosis
was performed with a running Prolene 5-0 suture (Ethicon,
Norderstedt, Germany). The length of popliteal arteriot-
omy was adapted carefully to the requirements of an opti-
mal cuff configuration during the suturing. In these proce-
dures, the precuffed end of the graft should not bemodified
in any way. The arteriotomy was performed long enough so
that the whole cuff could be sewn without modification. In
particular, the arteriotomy must not be too long, because
this would stretch the cuff on the longitudinal axis and
could compromise the cuff in the transverse axis. No exact
length of required popliteal artery was defined in the pro-
tocol, and the decision concerning the length of the arteri-
otomy as well as the further technique for the suture of the
cuff was left at the discretion of the surgeon. An intraoper-
ative angiogramwas obligatory only when an intraoperative
technical error was suspected or when a more proximal
stenosis (not identified preoperatively) was assumed during
the flushing maneuver from the common femoral artery.
The proximal anastomosis was performed end-to-side
with the common femoral artery. When necessary, ade-
quate inflow was established before the bypass by intraop-
erative balloon angioplasty or retrograde disobliteration of
the iliac vessels.
Postoperative care and follow-up. On postoperative
day 3 to 5, all patients underwent a control DSA of the
operated-on limb when no intraoperative angiography had
been performed (Fig 2). An intraoperative angiography was
not obligatory according to the study protocol, and the
decision was left to surgeon’s discretion.
All patients received anticoagulation for 2 days postop-
eratively with low-molecular-weight heparin at a prophy-
lactic dose of dalteparin at 5000 IU per day. On the third
postoperative day, when no contraindications such as major
wound healing disorder or another planned operation were
present, further anticoagulation was initiated with anti-
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antiplatelet or warfarin therapy reached effective levels. The
standardized postoperative anticoagulation scheme in-
cluded daily antiplatelet therapy (100 mg of aspirin or 75
mg of clopidogrel in cases of aspirin intolerance) when two
or more tibial or peroneal vessels were patent. When bal-
loon angioplasty with a stent was performed intraopera-
tively, clopidogrel was added to the aspirin anticoagulation
for 6 weeks.
Daily warfarin derivatives were administered to compli-
ant patients with only one patent crural vessel, even when
they presented with claudication or after revision for bypass
occlusion or thrombus formation at the distal anastomosis
and when no contraindications were present (optimal in-
ternational normalized ratio of 2.5 to 3.5). Patients with
prior dual antiplatelet therapy with aspirin and clopidogrel
because of coronary stents were prescribed oral anticoagu-
lation, if needed according to protocol, only after consul-
tation with cardiologists.
The follow-up protocol included office visits, clinical
Fig 2. Postoperative digital subtraction angiography of the left
limb, with focus on the distal precuffed end-to-side anastomosis.examination with recording of ABI, and color-coded du-plex ultrasound imaging at 3, 6 and 12 months postopera-
tively and every 6 months thereafter. Patients’ data were
collected in a SPSS 14.00 database (SPSS Inc, Chicago, Ill).
Kaplan-Meier survival analysis for primary outcome param-
eters was performed with Stata 10.0 (StataCorp, College
Station, Tex).
RESULTS
Between March 2005 and August 2007, 135 AK fem-
oropopliteal bypasses were implanted in 134 patients (110
men) using the Dynaflo graft in three vascular centers in
Germany (Fig 1). Table I summarizes the demographics
and cardiovascular risk factors of the group, typical for
patients with PAD. The overall mean patient age was 66
years (range, 39-86 years). Before surgery, 112 patients
(83%) were receiving antiplatelet therapy with aspirin, 60%
were receiving angiotensin-converting enzyme inhibitors,
and 58% were receiving -blockers. The mean preoperative
serum creatinine value was 1.1 mg/dL (range, 0.5-2.7;
normal value 1.3 mg/dL).
Prior revascularization of the ipsilateral limb or iliac
arteries had been done in 39 cases (29%), as summarized in
Table II. Six patients (4.6%) had undergone minor ampu-
tation of the affected limb before bypass graft implantation.
The patients with claudication had a mean preoperative
ABI of 0.6 (range, 0.2-1.1), and those with critical limb
ischemia had a mean ABI of 0.3 (range, 0,1-0,6). Five
patients (5.1%) were excluded from the calculation of mean
ABI because of an ABI 1.5 and renal insufficiency or
diabetes mellitus due to media sclerosis. The mean preop-
erative free-of-pain walking distance in the patients with
intermittent claudication was 90 m (range, 10-200 m).
A patent BK popliteal artery was a requirement to
Table I. Demographics and risk factors of 134 patients
assigned to receive an above-knee grafta
Risk factor
No. of grafts
(n  135)
or mean value
Percentageb
or range
Patient age, y 66 39-86
Male 110 81
Female 25 19
PAD stage
Claudication 99 73
Critical limb ischemia 36 27
SFA occlusion 20 cm 125 92.6
Coronary artery disease 48 36
Prior myocardial infarction 30 22
Diabetes mellitus 42 31
Noninsulin dependent 23 17
Insulin dependent 19 14
Hypertension 113 84
Hyperlipidemia 56 42
Current and former smokers 104 77
Current smokers 71 53
Renal insufficiency 31 23
PAD, Peripheral arterial disease; SFA, superficial femoral artery.
aOne patient received a bilateral graft implantation.
bN  135 grafts, according to 100%.perform AK revascularization. In 77 extremities (57%), all
JOURNAL OF VASCULAR SURGERY
May 20091206 Rückert et althree crural vessels were patent, whereas 33 (24%) had two,
and 25 (19%) had only one patent tibial or peroneal vessel.
In 88% of the grafts, the diameter was 7 mm, and only 12%
had an 8-mm diameter. The surgeon decided the diameter
of the graft according to the diameter of the common
femoral and the recipient artery. None of the grafts was
ringed.
In addition to the femoropopliteal bypass, 12 patients
(9%) required an intraoperative optimization of inflow to
the common femoral artery through balloon angioplasty or
retrograde ring-assisted endarterectomy and angioplasty of
the iliac arteries. No complications affecting the outcome
of the femoropopliteal bypass resulted from the interven-
tion on the iliac arteries.
Intraoperative angiography was done in 31 of the 135
limbs, and the remaining 104 had fine-needle angiography
on postoperative day 3 to 5. No technical errors were
identified in the postoperative angiogram and therefore no
early elective revisions required. At the time of dismissal, 81
patients (60%) were receiving anticoagulation with anti-
platelet agents (aspirin or clopidogrel), 41 (30%) had a
combination of aspirin and clopidogrel, and 12 (9%) were
receiving oral warfarin. Two patients in our series had prior
oral anticoagulation, so that a total of 10 patients (7.4%)
had a change of anticoagulation to warfarin derivatives
postoperatively.
During follow-up, the anticoagulation was changed
from antiplatelet agents to warfarin derivatives in 11 pa-
tients. The indication was bypass occlusion with revision in
order to preserve secondary patency in five patients at 7, 8,
11, 13, and 17 months, respectively, and thrombus in the
distal anastomosis with high risk of distal embolization or
occlusion in another patient at 12 months. The remaining
four patients received warfarin derivatives for cardial indi-
cation between 6 and 18 months postoperatively.
Complications were observed in 39 patients (29%),
with bypass failure (29 cases) and thrombus accumulation
at the distal anastomosis (4 cases) being the most severe.
No bypass infection was reported. Minor complications
included wound infection (5%), postoperative hematoma
(3%), and perigraft seroma formation (2%). Six patients
(4.4%) died during follow-up, and one died 30 days
Table II. Revascularization procedures of the affected
limb preceding the above knee bypass
Interventions/operations No. %
None 96 71
PTA with or without stent
Of the SFA 10 7
Of iliac arteries 15 11
Femoral artery patch angioplasty 7 5
Aortobifemoral bypass 7 5
AK femoropopliteal bypass 2 1.5
AK, Above knee; PTA, percutaneous transluminal angioplasty; SFA, super-
ficial femoral artery.postoperatively for an operative mortality rate of 0.7%.Graft patency. After a mean follow-up of 18 months
(range, 1-31 months) 29 grafts had failed, defined as oc-
clusion or intervention was required to preserve patency.
The cumulative primary patency rate of the Dynaflo graft at
6, 12, 18, and 24 months was 90%, 83%, 74%, and 72.5%,
respectively (Fig 3). The Kaplan-Meier analysis tables are
available in Appendices I-III (online only). Four patients
underwent reoperation or a change in anticoagulation ther-
apy to preserve patency, so that the primary assisted patency
rates at 6, 12, 18, and 24 months were 92.4%, 86.2%,
77.6%, and 74.6%, respectively (Fig 4). In one patient with
a potentially failing graft, thrombus material was removed
from the distal anastomosis by thrombectomy. Two pa-
tients underwent surgery to optimize inflow, and another
patient’s anticoagulation was changed to oral warfarin be-
cause of thrombus material in the distal anastomosis. One
of the two surgically treated patients had a severe stenosis of
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Fig 3. Cumulative primary patency after above knee bypass with
the Dynaflo (Bard Peripheral Vascular Inc, Tempe, Ariz) graft
using Kaplan-Meier analysis.
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Fig 4. Cumulative assisted primary patency after above knee by-
pass with the Dynaflo (Bard Peripheral Vascular Inc, Tempe, Ariz)
graft using Kaplan-Meier analysis.the common femoral artery above the proximal anastomo-
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tending to the proximal anastomosis. The second patient
had stenosis of the external iliac artery and the common
femoral artery on 1-year follow-up, which was treated with
a hybrid procedure of balloon angioplasty and stent of the
iliac artery and patch angioplasty of the common femoral
artery.
Secondary procedures included simple thrombectomy
in six patients (4.4%), thrombectomy with revision of the
distal anastomosis in another six (4.4%), and a redo proce-
dure with BK revascularization in three (2.2%). The latter
three patients with occluded Dynaflo grafts were consid-
ered secondary failures and excluded from further evalua-
tion in the study. Ten patients (7.4%) with bypass occlusion
and stable claudication were managed conservatively. The
resulting secondary patency rates at 6, 12, 18 and 24
months were 93%, 88.6%, 85.2%, and 82,2%, respectively
(Fig 5).
ABI and walking distance. The mean postoperative
ABI of the entire group was 1.2 (range, 0.7-1.5). Claudi-
cant patients had a mean postoperative ABI of 1.2 (range,
0.9-1.5), and patients with critical ischemia had a postop-
erative mean ABI of 1.0 (range, 0.7-1.2). The postopera-
tive measurement of free-of-pain walking distance on the
treadmill was discontinued when the patient was free of
pain after 200 m. This occurred in 55% of the claudication
patients postoperatively. The mean postoperative free-of-
pain walking distance of the rest of this group was 112 m
(range, 50-200 m).
Wound healing and limb salvage. Among the 36
patients with critical limb ischemia, 25 had ulcers or gan-
grene and 11 had pain at rest. Postoperative improvement
of pain occurred in all but one of these 11 patients. This
patient had a vital extremity with good perfusion, and the
analgetic therapy was extended. The median visual analog
scale score for pain was 7 preoperatively and 3 at 1 week
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Fig 5. Cumulative secondary patency after above knee bypass
with the Dynaflo (Bard Peripheral Vascular Inc, Tempe, Ariz) graft
using Kaplan-Meier analysis.postoperatively. Among the 25 extremities with ulcers organgrene, complete healing of the wounds was achieved
4 weeks postoperatively in 14 cases, whereas nine patients
required minor amputation. Despite a functioning bypass,
one patient required a BK amputation early postopera-
tively. No healing disorders of the amputation wounds
were observed. The remaining patient had a chronic wound
that did not heal despite adequate revascularization and
received further conservative treatment.
Seven limbs (5%) were unsalvageable, and major ampu-
tation was performed despite a patent graft in two. The
primary indication for revascularization of these limbs was
critical limb ischemia in five and claudication in two. The
cumulative 24-month limb salvage rate was 95% in the
entire group of patients independent of the PAD stage and
86% in the subgroup of 36 patients with critical limb
ischemia.
DISCUSSION
In the era of endovascular therapy with the application
of innovative techniques such as subintimal recanalization,
laser-assisted techniques, and flexible or covered stents in
the area of the SFA, conventional vascular surgery appears
to be on the decline.11-16 Nevertheless, although the idea
of achieving endovascular recanalization of the SFA also in
TASC C and D lesions and reserving surgery for cases of
failed endovascular therapy is appealing, no randomized
controlled studies have compared bypass with PTA to give
a reliable answer. To date, long-term results of PTA are still
inferior to surgery.1 Therefore, femoropopliteal bypass re-
mains the gold standard inmost vascular centers for chronic
occlusions of the SFA that are 20 cm.
The discussion about the best bypass material seems to
have been answered: Several studies, including two pub-
lished meta-analyses, proved the superiority of vein, even
for AK bypasses.2-4 Nevertheless, many vascular surgeons
are reluctant to use an available great saphenous vein for AK
revascularization because of the potential future need for a
more distal BK revascularization.
The ideal vascular bypass graft should replicate the
mechanical properties of native artery perfectly tomaximize
patency. In particular, it would demonstrate viscoelasticity
for efficient pulsatile flow, matched compliance to prevent
intimal hyperplasia, and have a burst pressure well above
the physiologic range of hemodynamic pressures.17 An
extensive body of literature describing effects of laminar
shear stress on endothelial cells has contributed to our
understanding of the interactions between shear stress and
blood vessels. Laminar shear stress is atheroprotective,
whereas oscillatory or disturbed shear stress correlates with
areas of atherosclerosis and intimal hyperplasia in vivo.18
The compliance mismatch between a vascular graft and
the native arterial wall also has a similar effect on intimal
hyperplasia formation. The role of flow stagnation is widely
accepted as a risk factor for intimal hyperplasia develop-
ment due to a low level of wall shear stress applied at certain
areas of the terminolateral anastomosis. Points subjected to
flow stagnation in the anastomosis include the floor, toe,
and heel of the anastomosis.19,20
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sion of intimal hyperplasia through optimization of hemody-
namic forces within the distal end-to-side anastomosis and is
based on evidence of an inverse relationship between mean
wall shear stress and intimal hyperplasia.8,21,22
The vortex, deemed to be beneficial in the Miller cuff,
has been replicated in most of the in vivo Distaflo grafts,
which are widely used as an alternative to interposition of
vein in the treatment of critical limb ischemia.
The Dynaflo graft represents the modification of Dis-
taflo for AK bypass procedures preserving the same pre-
cuffed form in the distal anastomosis. Only minor further
modifications were made to adjust the Dynaflo graft to the
AK segment of the popliteal artery. The larger cuff increases
the flow potential of the graft for larger anastomotic sites
such as found in a femoropopliteal AK bypass.
Two clinical trials demonstrated noninferiority con-
cerning primary and secondary graft patency and limb
salvage rates when comparing a precuffed ePTFE graft
(Distaflo, Bard Peripheral Vascular Inc, Tempe, Ariz) with
a vein-cuffed ePTFE graft for infragenicular arterial bypas-
ses.9,10 Satisfactory patency rates have also been described
for the Distaflo graft in several other studies.23-25 The
5-year patency rate of ePTFE AK femoropopliteal bypass is
between 35% and 52% in randomized trials, with vein
achieving cumulative patency rates of 74% to 76%.1,3,5,26,27
The configuration of the distal cuff of the Dynaflo graft
(Bard Peripheral Vascular Inc, Tempe, Ariz) aims at im-
proving patency rates of AK femoropopliteal bypass by
optimizing the hemodynamics through anastomotic engi-
neering of the distal anastomosis.
In the present prospective multicenter study, the cu-
mulative primary and secondary patency at 24 months of
follow-up were 72.5% (confidence interval [CI], 62.6-
80.2%) and 82% (CI, 73.1-88.5%) respectively. Intermit-
tent claudication was present in 73% of the patients in the
present cohort, which also explains the low 5% rate of major
amputation in our series. Nevertheless, two limb losses
occurred in patients with intermittent claudication before
the primary operation. Both patients presented on fol-
low-up with progressive infrapopliteal atherosclerotic dis-
ease and bypass occlusion. In one patient embolization of
the tibial vessels from a thrombus in the graft cuff was
suspected.
Four patients in the present series were diagnosed with
relevant thrombus formation in the cuff of the distal anas-
tomosis. In two patients the thrombusmass was limited and
required no intervention. One patient was treated with oral
anticoaglation, and the remaining patient underwent by-
pass revision.
The graft managed with life-long oral anticoagulation
was considered a failing graft (primary patency failure)
because a prophylactic although nonsurgical intervention
was required, which nevertheless has an important conse-
quence on the patient’s quality of life.
Formation of thrombus in the cuff of the distal anasto-
mosis could be a drawback of the Dynaflo prosthesis.
Furthermore in our experience, surgical thrombectomy ofan occluded graft frequently required revision of the distal
anastomosis to fully extract the thrombus mass from the
cuff, which was difficult to achieve over an inguinal ap-
proach with a Fogarty maneuver only. An intraoperative
DSA was considered obligatory for the same reason.
The Dynaflo graft is thinner ePTFE in the area of the
graft cuff, which might provide better viscoelastic proper-
ties and better compliance. Because of this property of the
cuff, especially careful handling of the graft during suture of
the distal anastomosis is needed.
Major drawbacks of our study are its descriptive char-
acter and the lack of a control group of patients undergoing
implantation of another bypass graft. Data from other
studies as well as meta-analyses are available, however, and
cautious comparison of these data with the results of the
present study seems to be reasonable. Thus in several
studies, ePTFE achieved cumulative patency rates of 50% to
77% after 2 years of follow-up.5,27-29
Klinkert et al2 reported in their meta-analysis cumu-
lative primary patency rates of 67% for ePTFE grafts
(2520 grafts) at 2 years of follow-up when all studies
were reviewed and 69% (643 grafts) when only random-
ized controlled trials were included. Therefore, consid-
ering the limitations of our study, we can cautiously
conclude that with 72.5% primary and 82% secondary
cumulative patency, the Dynaflo graft seems to perform
at least equally at 2 years of follow-up compared with
standard ePTFE grafts.2
Randomized controlled trials, based on the results ob-
tained in the present study, are warranted because only
these type of high-level evidence studies, including later
meta-analyses, can definitely answer the everlasting ques-
tion of the best conduit for AK femoropopliteal bypass.
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Time, months Total, No. Failed, No. L
.01 135 6
1 129 1
2 128 1
3 123 0
4 120 3
5 113 1
6 111 1
7 109 4
8 101 0
9 97 1
10 94 0
11 90 1
12 86 2
13 83 2
14 78 2
15 72 1
16 67 1
17 63 1
18 58 1
19 51 0
20 50 0
21 45 1
22 41 0
23 38 0
24 35 0
25 32 0
26 24 0
27 22 0
28 17 0
29 11 0
30 6 0
31 1 0
CI, Confidence interval.r primary patency
ost, No. Function Error 95% CI
0 0.9556 0.0177 0.9038-0.9798
0 0.9481 0.0191 0.8943-0.9749
4 0.9407 0.0203 0.8850-0.9699
3 0.9407 0.0203 0.8850-0.9699
4 0.9172 0.0239 0.8554-0.9533
1 0.9091 0.0251 0.8454-0.9474
1 0.9009 0.0261 0.8353-0.9413
4 0.8679 0.0299 0.7958-0.9158
4 0.8679 0.0299 0.7958-0.9158
2 0.8589 0.0309 0.7851-0.9088
4 0.8589 0.0309 0.7851-0.9088
3 0.8494 0.0320 0.7735-0.9014
1 0.8296 0.0342 0.7498-0.8859
3 0.8096 0.0362 0.7263-0.8698
4 0.7889 0.0381 0.7022-0.8529
4 0.7779 0.0391 0.6894-0.8440
3 0.7663 0.0402 0.6758-0.8346
4 0.7541 0.0414 0.6616-0.8247
6 0.7411 0.0427 0.6462-0.8142
1 0.7411 0.0427 0.6462-0.8142
5 0.7411 0.0427 0.6462-0.8142
3 0.7247 0.0448 0.6256-0.8016
3 0.7247 0.0448 0.6256-0.8016
3 0.7247 0.0448 0.6256-0.8016
3 0.7247 0.0448 0.6256-0.8016
8 0.7247 0.0448 0.6256-0.8016
2 0.7247 0.0448 0.6256-0.8016
5 0.7247 0.0448 0.6256-0.8016
6 0.7247 0.0448 0.6256-0.8016
5 0.7247 0.0448 0.6256-0.8016
5 0.7247 0.0448 0.6256-0.8016
1 0.7247 0.0448 0.6256-0.8016
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Time, months Total, No. Failed, No. Lost, No. Function Error 95% CI
.01 135 4 0 0.9704 0.0146 0.9230-0.9888
1 131 1 0 0.9630 0.0163 0.9133-0.9844
2 130 1 4 0.9556 0.0177 0.9038-0.9798
3 125 0 3 0.9556 0.0177 0.9038-0.9798
4 122 2 4 0.9399 0.0206 0.8834-0.9695
5 116 1 1 0.9318 0.0220 0.8729-0.9639
6 114 1 1 0.9236 0.0233 0.8626-0.9582
7 112 4 4 0.8906 0.0277 0.8221-0.9338
8 104 0 4 0.8906 0.0277 0.8221-0.9338
9 100 1 2 0.8817 0.0288 0.8112-0.9271
10 97 0 4 0.8817 0.0288 0.8112-0.9271
11 93 1 3 0.8722 0.0300 0.7995-0.9199
12 89 1 1 0.8624 0.0312 0.7874-0.9124
13 87 2 2 0.8426 0.0335 0.7634-0.8970
14 83 2 4 0.8223 0.0356 0.7393-0.8810
15 77 1 4 0.8116 0.0367 0.7267-0.8725
16 72 1 3 0.8004 0.0379 0.7133-0.8635
17 68 1 4 0.7886 0.0391 0.6992-0.8541
18 63 1 6 0.7761 0.0405 0.6843-0.8442
19 56 0 1 0.7761 0.0405 0.6843-0.8442
20 55 1 5 0.7620 0.0421 0.6670-0.8332
21 49 1 3 0.7464 0.0440 0.6477-0.8212
22 45 0 4 0.7464 0.0440 0.6477-0.8212
23 41 0 3 0.7464 0.0440 0.6477-0.8212
24 38 0 3 0.7464 0.0440 0.6477-0.8212
25 35 0 8 0.7464 0.0440 0.6477-0.8212
26 27 0 2 0.7464 0.0440 0.6477-0.8212
27 25 0 6 0.7464 0.0440 0.6477-0.8212
28 19 0 7 0.7464 0.0440 0.6477-0.8212
29 12 0 5 0.7464 0.0440 0.6477-0.8212
30 7 0 6 0.7464 0.0440 0.6477-0.8212
31 1 0 1 0.7464 0.0440 0.6477-0.8212CI, Confidence interval.
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Time, months Total, No. Failed, No. Lost, No. Function Error 95% CI
.01 135 3 0 0.9778 0.0127 0.9327-0.9928
2 132 1 4 0.9704 0.0146 0.9230-0.9888
3 127 0 3 0.9704 0.0146 0.9230-0.9888
4 124 2 4 0.9547 0.0181 0.9019-0.9794
5 118 2 1 0.9385 0.0211 0.8808-0.9688
6 115 1 1 0.9304 0.0224 0.8703-0.9632
7 113 2 4 0.9139 0.0249 0.8498-0.9514
8 107 0 4 0.9139 0.0249 0.8498-0.9514
9 103 1 2 0.9050 0.0262 0.8386-0.9450
10 100 0 4 0.9050 0.0262 0.8386-0.9450
11 96 1 3 0.8956 0.0275 0.8266-0.9382
12 92 1 1 0.8859 0.0289 0.8143-0.9310
13 90 0 5 0.8859 0.0289 0.8143-0.9310
14 85 1 4 0.8755 0.0304 0.8011-0.9233
15 80 1 4 0.8645 0.0319 0.7872-0.9152
16 75 0 3 0.8645 0.0319 0.7872-0.9152
17 72 0 4 0.8645 0.0319 0.7872-.09152
18 68 1 6 0.8518 0.0339 0.7704-0.9060
19 61 0 1 0.8518 0.0339 0.7704-0.9060
20 60 1 5 0.8376 0.0362 0.7515-0.8959
21 54 1 3 0.8221 0.0387 0.7307-0.8848
22 50 0 4 0.8221 0.0387 0.7307-0.8848
23 46 0 3 0.8221 0.0387 0.7307-0.8848
24 43 0 3 0.8221 0.0387 0.7307-0.8848
25 40 0 9 0.8221 0.0387 0.7307-0.8848
26 31 0 2 0.8221 0.0387 0.7307-0.8848
27 29 0 7 0.8221 0.0387 0.7307-0.8848
28 22 0 7 0.8221 0.0387 0.7307-0.8848
29 15 0 5 0.8221 0.0387 0.7307-0.8848
30 10 0 9 0.8221 0.0387 0.7307-0.8848
31 1 0 1 0.8221 0.0387 0.7307-0.8848CI, Confidence interval.
